SCHEMBL6480181

SCHEMBL6480181

Cc1cccc(C)c1C(=O)n1c(C)cc2cc(NC(=O)C3CCCC3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.51
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
UBE2M P61081 1/20 0.43
DCUN1D1 Q96GG9 1/20 0.43
ELANE P08246 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480935 0.99 NPSR1 (0.50) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6490780 0.98 NPSR1 (0.48) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6489189 0.96 HSD17B10 (0.46) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6480891 0.90 NPSR1 (0.50) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6480722 0.89 NPSR1 (0.49) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6481059 0.89 NPSR1 (0.49) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6492262 0.88 NPSR1 (0.47) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6481448 0.88 GRM4 (0.48) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6480771 0.87 NPSR1 (0.46) NPSR1MAOAMAOBALDH1A1SMN1; SMN2
SCHEMBL6492249 0.87 PARP1 (0.48) NPSR1ALDH1A1SMN1; SMN2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 NPSR1 556/4885MAOA 28/4885MAOB 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.